Attitude towards positive *Toxoplasma* quantitative PCR results in allogeneic hematopoietic stem cell

transplantation recipients: a 10-year retrospective analysis.

Alienor Xhaard[1], Alban Villate[2], Samia Hamane[3], David Michonneau[1,4,7], Jean Menotti[5], Marie

Robin[1], Flore Sicre de Fontbrune[1], Nathalie Dhédin[6], Régis Peffault de la Tour[1,7], Gérard Socié[1,4,7*],

and Stéphane Bretagne[3,7*]

1 Service d'hématologie-greffe, Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris, France

2 Service d'hématologie et thérapie cellulaire, CHRU Tours, Tours, France

3 Laboratoire de mycologie-parasitologie, Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris,

France

4 INSERM UMR 976 (Team Insights), Université Paris Diderot, Paris, France

5 Laboratoire de mycologie-parasitologie, Hospices Civils de Lyon, Lyon, France

6 Service d'hématologie adolescents jeunes adultes, Hôpital Saint-Louis, APHP, Université Paris

Diderot, Paris, France

7 Université Paris Cité

* These authors contributed equally to this work

Running title: *Toxoplasma* qPCR in alloHSCT recipients

Abstract: 198 words

Article: 3 000 words

Table: 1

Figures: 4

References: 30

Corresponding author:

Dr. Aliénor Xhaard

Service d'hématologie-greffe, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université

Paris-Diderot

1 avenue Claude Vellefaux, 75475 Paris, Cedex 10, France.

Phone: +33 1 42 49 96 39

Fax: +33 1 42 49 96 36

E-mail: alienor.xhaard@aphp.fr

ORCID: 0000-0002-4449-989X

Abstract

A strategy of systematic blood *Toxoplasma gondii* DNA screening using real-time quantitative polymerase chain reaction (qPCR) has been implemented in allogeneic hematopoietic stem cell transplantation (alloHSCT) recipients in our hospital to prevent death due to toxoplasmosis. We conducted a retrospective monocentric study to describe the epidemiology of toxoplasmosis in alloHSCT recipients, and the therapeutic attitude in qPCR-positive patients.

From 2011 to 2020, *Toxoplasma* infection and disease (central nervous system involvement) were present in 3.5% and 0.56% of 1 257 alloHSCT recipients, respectively. Toxoplasmosis contributed to death in three patients. qPCR was positive before D100 in 30 patients without and 14 with toxoplasmosis prophylaxis. When available (n= 24), the DNA kinetics showed an increase until the implementation of anti-*Toxoplasma* treatment, followed by a decrease. However, the optimal dosage of anti-*Toxoplasma* regimen is not straightforward and either prophylactic or intermediate-dose controlled the parasitic load in a significant proportion of cases. Treatment could also be discussed in asymptomatic patients with a low circulating parasitic load at diagnosis.

Associating close clinical and qPCR monitoring, and integrating the quantification of the parasitic load assessed by qPCR, appears a reasonable strategy to avoid full-blown toxoplasmosis and to limit the side effects of anti-*Toxoplasma* treatments.

Introduction

Toxoplasmosis is a zoonosis caused by *Toxoplasma gondii*, an intracellular coccidian parasite with

numerous warm-blood intermediate hosts, and cats as the definite host. In humans, primary infection

occurs after ingestion of cysts containing undercooked meat or oocysts from the environment. Primary

infection, usually asymptomatic, leads to the latency of bradyzoites in astrocytes, retina cells and

muscles. In immunocompromised patients, toxoplasmosis mainly results from reactivation of latent

cysts and its incidence depends on geographical endemicity, highly dependent on culinary habits.

Toxoplasmosis in allogeneic hematopoietic stem cell transplantation (alloHSCT) recipients remains a

matter of concern (1). Prophylaxis using cotrimoxazole (CTX, trimethoprim/sulfamethoxazole) is

recommended in seropositive patients (2–4), but usually postponed until full engraftment, for fear of

possible hematological toxicity. Most cases occur between three and 26 weeks post-alloHSCT (5–7),

but later or sooner occurrences have been reported (8). Outcomes were particularly dismal before the

2000s, with an estimated attributable mortality rate over 50%, probably due to a late diagnosis (9–11).

Early *Toxoplasma* detection, using real-time quantitative polymerase chain reaction (qPCR)

monitoring, has improved survival (7). Indeed, circulating DNA detection usually precedes symptoms

by 14-16 days (5,12). However, qPCR screening leads to the observation of qPCR-positive poorly

symptomatic or asymptomatic patients: clinicians can then be reluctant to prescribe drugs possibly

responsible for hematological toxicity (CTX or other sulfonamides). Moreover, it is not yet known if

all qPCR-positive patients will develop *Toxoplasma* disease in the absence of specific treatment, and

there are no data and no recommendations on the best therapeutic option for asymptomatic patients

with positive qPCR.

In our center, a strategy of weekly *Toxoplasma* qPCR screening of alloHSCT recipients has been

implemented for more than 10 years. The aims of this observational monocentric retrospective study

were to describe the epidemiology of toxoplasmosis in alloHSCT recipients, and the attitude regarding

anti-*Toxoplasma* treatment in qPCR-positive patients.

Patients and methods

Patients and definitions

The study was conducted in the Hematology Transplantation Ward at Saint-Louis Hospital (Paris,

France). AlloHSCT recipients transplanted between January 2011 and December 2020 were included.

Data were collected from the PROMISE database and local medical reports.

Toxoplasma infection and disease were defined according to the European Society for Blood and

Marrow Transplant-Infectious Diseases Working Party guidelines (13)**.** *Toxoplasma* infection was

defined as ≥ one positive PCR test from blood, cerebrospinal fluid or bronchoalveolar lavage fluid, in

a patient without evidence of organ involvement, with or without fever. *Toxoplasma* disease was

defined as the presence of *Toxoplasma* infection, plus clinical, radiological or pathological evidence of

organ involvement. The day of the first positive qPCR was defined as the day of toxoplasmosis

diagnosis. Mortality was considered toxoplasmosis-attributable if it occurred with positive qPCR or

compatible clinical signs, and in the absence of alternative diagnosis. In patients for whom another

cause of death was identified but who died with a positive qPCR, toxoplasmosis was considered as a

death-contributing factor (13).

Microbiological and diagnostic investigations

Prior to alloHSCT, an anti-*Toxoplasma* immunoglobulin-G (IgG) assay was systematically performed

in donors and recipients (recipient within three months and donor within 28 days, respectively). The

in-house qPCR targeted the *Toxoplasma*-specific AF 146527 DNA sequence (14). qPCR monitoring

was performed on venous blood samples (1 ml) once weekly, regardless of serologic status from

alloHSCT until D100, and thereafter at the discretion of the physician in cases of graft-versus-host-

disease (GVHD), prolonged immunosuppression, or hospitalization (**Figure 1a**). qPCR results were

expressed as a quantification cycle (Cq) (15), with a low parasitic load corresponding to Cq between

36 and 45. The laboratory subscribed to an independent external quality control for both *Toxoplasma*

serology and qPCR.

In case of positive *Toxoplasma* qPCR, the decision over whether to perform a diagnostic work-up was

made by the physician in charge and usually included central nervous system (CNS) computed-

tomography (CT-scan) or magnetic-resonance imaging, thorax and abdomen CT-scans and fundus

ophthalmoscopy. Blood control qPCR was performed once to twice weekly after the first positive

sample.

*Anti-*Toxoplasma *prophylaxis and treatment*

Toxoplasma gondii and *Pneumocystis jirovecii* prophylaxis using prophylactic CTX (400mg/day or

800mg/day given three days/week), pyrimethamine/sulfadoxine (P/So, 1 500mg/75mg once weekly)

or atovaquone (750mg bid) was given to all patients after neutrophil recovery. Historically, the

preferred prophylaxis in our center was P/So, as one of our previous publications seemed to show a

benefit of this treatment (16), but commercialization ceased in 2017. From then on, the most used

prophylaxis in our center has been CTX. However, atovaquone was preferentially used in patients with

cytopenia, due to concerns about the possible hematological toxicity of CTX.

At reception of the first positive *Toxoplasma* qPCR, the therapeutic option was decided by the treating

physician and is described in **Figure 1b**. Since qPCR was performed as a screening test before D100

and according to clinical suspicion later, often in a context of GVHD, we separated the two situations

for further analyses.

Ethical consideration

The Institutional Review Board approved this study of the Saint-Louis Hospital. All patients gave their

written consent for data collection. The study followed the Declaration of Helsinki.

Statistical analyses

Continuous variables are expressed as median [IQR] and compared using Dunn's test with Bonferroni

correction. Categorical variables are expressed as frequencies (percentages) and compared using

Fisher's test. All analyses were performed using SAS version 9.4.6 (SAS Institute Inc., Cary, NC,

USA). A two-tailed significance level $p<0.05$ was used.

Results

Study population and toxoplasmosis incidence

During the 10-year study period, 1 258 alloHSCTs were performed in our center, including 1 257 donor/recipient couples with available donor and recipient pre-alloHSCT *Toxoplasma gondii* serology. Anti-*Toxoplasma* IgG were positive in 734 recipients (58.3%) and 379 donors (30.1%). Excluding 65 cord blood alloHSCTs, anti-*Toxoplasma* IgG were positive in 264/579 (45.6%) of related donors and in 114/613 (18.6%) of unrelated adult donors. The combination of donor and recipient serology was donor positive/recipient positive: 272 (21.6%), donor negative/recipient positive: 462 (36.8%), donor positive/recipient negative: 107 (8.5%), and donor negative/recipient negative: 416 (33.1%). Median age of the 1 258 patients was 45.6 years [IQR: 28-58]: 31 years [IQR: 21-46] for *T. gondii* seronegative patients and 53 years [IQR: 40-55] for seropositive patients.

During the study period, 22 154 qPCR tests were performed (median/patient: 15 [IQR: 9-21]) without significant variation according to the year of sampling. In total, 52 patients (4.13%) had at least one *T. gondii* positive qPCR, including 44 before D100. A median of five cases were diagnosed annually. Seven patients were diagnosed with probable *Toxoplasma* disease (with radiological evidence of CNS lesion in all patients and positive cerebrospinal fluid qPCR in the two patients for whom lumbar puncture was performed). In total, *Toxoplasma* infection and disease were diagnosed in 3.5% and 0.56% of our patients, respectively.

Patient characteristics

Out of the 52 patients with at least one *Toxoplasma gondii* positive qPCR after alloHSCT, 31 were male (56.9%). Median age at alloHSCT and at toxoplasmosis was 42 ([IQR: 16-52 and 17-52], respectively). **Table 1** presents patient characteristics. Median time from alloHSCT to first positive qPCR was 26 days [IQR: 17-60]. Before alloHSCT, five patients were anti-*Toxoplasma* IgG negative (including three patients heavily pre-treated for non-Hodgkin lymphoma and acute leukemia). Two patients, both seropositive, had a *Toxoplasma* reactivation before alloHSCT (one was qPCR-positive during a septic shock, was treated by CTX; one with an ocular toxoplasmosis was treated by atovaquone).

qPCR was positive before D100 in 44 patients (84.6%), including 30 without and 14 with toxoplasmosis prophylaxis. qPCR was positive later after alloHSCT in patients with prophylaxis than

1 in patients without prophylaxis (median: 48 days [IQR: 28-61] versus median: 19 days [IQR: 14-25],

2 p= 0.0003). Patients without prophylaxis were mainly diagnosed before D30 (83.3%), rather than

3 between D31 and D100 (16.7%), while patients receiving anti-*Toxoplasma* prophylaxis were mainly

4 diagnosed between D31 and D100 (64.3%) rather than before D30 (35.7%) (p= 0.004). At

5 toxoplasmosis diagnosis, patients without prophylaxis more frequently received mycophenolate

6 mofetil (43.3%, versus 0%, p= 0.0034), and were more profoundly lymphopenic (median: 0.1 [0-

7 0.25], versus 0.4 [0.1-1-1], p= 0.0.24). The median number of positive qPCR and the median time

8 from first positive to first negative qPCR were not significantly different between patients without or

9 with prophylaxis. Treatment tolerance was excellent at prophylactic dosage, without toxicity-related

10 treatment withdrawal. At non-prophylactic dosage, treatment was changed for toxicity in 8/25 (32%)

11 patients (hematological: six, liver: two, renal: one). The fatality rate of patients without or with

12 prophylaxis was not significantly different (33.3% versus 64.3%): the main cause of death was GVHD

13 (50-55.6%). Two patients died of GVHD with a positive qPCR (although with decreasing parasitic

14 load), while one patient died of acute lymphoblastic leukemia (ALL) relapse and CNS toxoplasmosis

15 (with negative blood qPCR).

16 *Analysis of qPCR results according to treatment*

17 *Diagnosis before D100 (**Table 1, Figure 2**)*

18 For the 30 patients without anti-*Toxoplasma* prophylaxis (**Table 1, Figure 2a**), control qPCR was

19 spontaneously negative in two patients with an initial single high Cq result (40 and 37.3, respectively),

20 who nevertheless subsequently started prophylactic treatment without toxoplasmosis recurrence.

21 Fifteen patients were started on pre-emptive treatment at prophylactic dosage: 10 (67%) became qPCR

22 negative, while five (33%) became qPCR negative only after prophylactic CTX was increased to 800-

23 2 400 mg/day. Thirteen patients started anti-*Toxoplasma* non-prophylactic treatment, including P/Sa

24 (n= 5), CTX 800mg/day (n= 5) and CTX 1 600-2 400mg/day (n= 3). Initial treatment was changed in

25 five cases for toxicity (n= 2, P/Sa), suspicion of malabsorption (n= 1, P/Sa), or persistently positive

26 qPCR (n= 2, CTX 800mg/day). Two patients (CTX 800 and 2 400mg/day, respectively) died of

27 GVHD with persistently positive qPCR after 29 and 12 days. Toxoplasmosis resolved with treatment

28 in all other cases.

To study the DNA kinetics (**Figure 3)**, we analyzed the parasitic load of 24 patients who had a qPCR result available either the day of treatment implementation or the previous day, and a qPCR result within seven days before and after treatment began. Before treatment, the median decrease of the Cq values was 1 Cq/day [0.5-1.5] (i.e., a median increase of 4.0 [1.1-30.3] parasites/ml of blood/day), and the median increase after treatment was 1.2 Cq/day [0.4-2.3] (i.e., a median decrease of 2.8 [1.1-13.8] parasites/ml of blood/day), assuming that the regression was linear between two points.

For the 14 patients diagnosed while receiving toxoplasmosis prophylaxis (**Table 1, Figure 2b**), the first qPCR was positive a median of 18 days [IQR: 8-34] after the start of prophylactic treatment. Prophylaxis was not modified in eight cases (57%) and qPCR became negative in all cases after 0 to 21 days. In six patients, prophylactic CTX was replaced by P/Sa (n= 3, including 2 CNS toxoplasmosis) or increased CTX dosage (n= 3 800-4 800mg/day). Toxoplasmosis eventually resolved in all patients.

Diagnosis after D100

Toxoplasmosis was diagnosed after D100 in eight patients, all receiving steroids for GVHD (n= 7) or post-transplant ALL relapse (n= 1). In six cases, qPCR was performed as part of a systematic screening for outpatients (n= 3) or inpatients (GVHD, n= 2; sepsis, n= 1). In the other two cases, qPCR was performed as part of the diagnostic work-up in patients with neurological symptoms, leading to CNS toxoplasmosis diagnosis. Six patients had breakthrough toxoplasmosis while receiving P/So (n= 1) or prophylactic CTX (n= 5). **Figure 4** presents treatment and patient evolution.

Discussion

Despite the high prevalence of anti-*Toxoplasma* IgG positivity (58.3% of alloHSCT recipients), toxoplasmosis was infrequent in our 10 year-long study, with 0.56% and 3.5% of our patients diagnosed with *Toxoplasma* disease and infection, respectively. The present prevalence of *Toxoplasma* reactivation (4.13%) is close to the prevalence reported in the most recent studies (3.9-4.1%) (8,17,18), whereas older studies reported higher figures, from 8.7 to 18.6% (5,7,19–21). This decrease can be ascribed to the decrease of seroprevalence of anti-*Toxoplasma* antibodies in the general

population (22). Other sources of differences include the seropositivity prevalence in the considered country (23), the screened population (only seropositive or all alloHSCT recipients (18)), the PCR assay used (the AF146527 DNA sequence being more sensitive than the B1 gene (24)), the number of positive PCR results considered for diagnosis (≥2 in (17), versus ≥1 in others), and the frequency of sampling (usually once weekly). The *Toxoplasma* reactivation decrease in European alloHSCT recipients can also be simply ascribed to a better acceptance of CTX as prophylaxis of both toxoplasmosis and pneumocystosis (20).

In our cohort, *Toxoplasma* reactivation diagnosed by systematic qPCR screening was mainly observed (58%) in patients before prophylaxis started, as previously reported (8,18,20). The first *Toxoplasma* qPCR was positive a median of 19 days after alloHSCT in our 30 patients diagnosed before the start of prophylaxis, earlier than historical or more recent reports (5,8,20). In 28 of these patients, a second PCR with an increased parasitic load definitively advocates for an ongoing multiplication of the parasite, and therefore prompt pre-emptive treatment. Moreover, the decrease of the parasitic load following treatment implementation is indicative of treatment effectiveness (25). Therefore, the qPCR screening is of utmost importance before prophylaxis is begun, or when the center policy is to avoid CTX (17).

We confirm that systematic qPCR screening is associated with a better prognosis of toxoplasmosis (7), as no death was directly attributable to toxoplasmosis in our cohort. However, the prognosis of toxoplasmosis patients was still dismal, with a fatality rate of 43% in patients diagnosed before D100, including 13/19 patients dying within six months from alloHSCT. This conclusion differs from that of Conrad et al., who reported a toxoplasmosis-attributable mortality of 43.5% (18). In our cohort, the decrease of the parasitic load definitively shows that the anti-*Toxoplasma* treatment was effective in controlling the parasite growth, acknowledging this is not sufficient to avoid death (GVHD was the main cause of death in our cohort, as already described (26)). The fatality rate was especially high (64%) in patients with a positive qPCR before D100 while receiving anti-*Toxoplasma* prophylaxis. One can wonder if the positivity of qPCR in these cases can be considered as a marker of global frailty and immunosuppression, placing these patients into a population at high risk of death.

If one can reach a consensus on the use of qPCR for screening alloHSCT recipients, there are no definite recommendations concerning drugs and dosage. Asymptomatic qPCR-positive patients receiving prophylaxis (n= 9) or not (n= 2) became negative on a following sample, before any treatment change or implementation. This can be expected according to Poisson's law in case of a parasitic load at the limit of detection of the qPCR, assuming that there are no technical false positive PCR results, and can support the choice to wait for a second positive result before starting anti-*Toxoplasma* treatment, as proposed by Aerts et al. (17). In case of a negative control qPCR, the hypothesis would be that these patients have cleared the infection, thanks to anti-*Toxoplasma* immune recovery.

We also report the occurrence of breakthrough *Toxoplasma* reactivation in 20 patients receiving prophylaxis (including CTX in 16 cases), although it is hard to evaluate observance for cases occurring late after alloHSCT. In these cases, the parasitic load was always low. Hypotheses to explain breakthrough toxoplasmosis are that the usual prophylaxis dosage is suboptimal to control the reactivation, or that gut GVHD alters prophylactic treatment absorption, although this did not lead in our observations on *Toxoplasma* disease. According to our findings, the implementation of a full-dose curative treatment might be avoided in asymptomatic patients with a low circulating parasitic load at diagnosis. The introduction of pre-emptive treatment at a prophylactic or intermediate dose actually led to *T. gondii* control in a significant proportion of cases: this strategy can be regarded as a reasonable option when associated with close clinical and qPCR monitoring integrating parasitic load quantification. These findings suggest that the tuning between parasite multiplication, immune resistance and drug dosage is probably not uniform and could be highly patient-specific.

Assuming that reactivation is the main explanation for *T. gondii* infection, most cases being diagnosed among donor negative/recipient positive alloHSCTs as already reported (11,13,18,20,27,28), this raises the issue of whether or not to include the seronegative patients into the qPCR screening strategy (11,13,18,20,27–29). In our cohort, five *Toxoplasma* infections occurred in pre-alloHSCT seronegative patients. The first reason for this finding is false-negative serology, due to an impaired immunity because of previous treatments, or to the waning of immunity after a very old infection, knowing that transmission of infection via the graft is also possible (11,18,27,28,30). To include

seronegative patients in the screening is a cost-effectiveness issue that should be balanced with the risk

of missing *Toxoplasma* disease, knowing that the seronegative population is growing (22).

The strength of our study is the large size of our cohort and the systematic screening of all alloHSCT

recipients over a 10-year period, using similar serological and molecular tools. However, the

retrospective nature of our study is a limit: sampling was not performed similarly in all patients,

making it difficult to interpret the kinetics of the parasitic load. Similarly, therapeutic attitudes were

dependent on physician decisions, in the absence of clear recommendations on the molecules and

doses to be used. Despite these limits, in cases of asymptomatic *Toxoplasma* infection diagnosed

before the start of prophylaxis, we report a good efficacy of a pre-emptive strategy, even at low doses

similar to that prescribed for prophylaxis. This strategy could decrease the toxicity of P/Sa or high-

dose CTX treatments. When occurring in patients already receiving anti-*Toxoplasma* prophylaxis, one

can also propose continuing without necessarily increasing the doses of CTX or changing molecules,

with close clinical and qPCR monitoring.

In conclusion, in this large cohort of alloHSCT recipients with systematic *Toxoplasma gondii* qPCR

screening until D100, we report a low rate of toxoplasmosis, with a low attributable mortality, if any.

It is important to start qPCR screening before engraftment, since most of our cases (57.7%) occurred

before D30, sometimes before engraftment, and to continue until D100, then according to clinical

suspicion (unexplained fever, central neurological signs). Optimal treatment doses in asymptomatic

patients with positive qPCR remains to be established, both in cases of the patient receiving

prophylaxis or not. In any case, we advocate for a close monitoring of the parasitic load using qPCR to

adjust therapeutic attitudes.

Acknowledgments

The authors wish to thank all the technical staff of the laboratory for performing the biological tests,

and nurses who took take care of the patients, as well as Ms. Sylvie Lengay for data extraction and Mr.

David Williams for manuscript editing.

Author contributions:

AX, AV, GS and SB designed the study protocol, conducted the search, extracting and analyzing data,

interpreted results, and wrote the manuscript. DM conducted the statistical analyses. SH, JM and SB

conducted and interpreted the qPCR tests. AX, AV, DM, MR, FSF, ND and RPL took care of patients.

All authors read and approved the manuscript before submission.

Conflict of interest

None.

References

1. Rauwolf KK, Floeth M, Kerl K, Schaumburg F, Groll AH. Toxoplasmosis after allogeneic haematopoietic cell transplantation—disease burden and approaches to diagnosis, prevention and management in adults and children. Clin Microbiol Infect. 2021 Mar;27(3):378–88.

2. Gea-Banacloche J, Masur H, Arns da Cuhna C, Chiller T, Kirchoff L, Shaw P, et al. Regionally limited or rare infections: prevention after hematopoietic cell transplantation. Bone Marrow Transplant. 2009 Oct;44(8):489–94.

3. on behalf of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation), Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, et al. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol. 2016 Sep;95(9):1435–55.

4. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective. Biol Blood Marrow Transplant. 2009 Oct;15(10):1143–238.

5. Martino R, Bretagne S, Einsele H, Maertens J, Ullmann AJ, Parody R, et al. Early Detection of Toxoplasma Infection by Molecular Monitoring of Toxoplasma gondii in Peripheral Blood Samples after Allogeneic Stem Cell Transplantation. Clin Infect Dis. 2005 Jan 1;40(1):67–78.

6. Lim Z, Baker B, Zuckermann M, Wade JJ, Ceesay M, Ho AYL, et al. Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation. J Infect. 2007 Feb;54(2):e83–6.

7. Bretagne S, Costa JM, Foulet F, Jabot-Lestang L, Baud-Camus F, Cordonnier C. Prospective study of toxoplasma reactivation by polymerase chain reaction in allogeneic stem-cell transplant recipients: T. gondii PCR for SCT recipients. Transpl Infect Dis. 2000 Sep;2(3):127–32.

8. Robin C, Leclerc M, Angebault C, Redjoul R, Beckerich F, Cabanne L, et al. Toxoplasmosis as an Early Complication of Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 Dec;25(12):2510–3.

9. De Medeiros BC, De Medeiros CR, Werner B, Loddo G, Pasquini R, Bleggi-Torres LF. Disseminated toxoplasmosis after bone marrow transplantation: report of 9 cases: Disseminated toxoplasmosis after BMT. Transpl Infect Dis. 2001 Mar;3(1):24–8.

10. Mele A, Paterson P, Prentice H, Leoni P, Kibbler C. Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature. Bone Marrow Transplant. 2002 Apr 1;29(8):691–8.

11. Derouin F, Devergie A, Auber P, Gluckman E, Beauvais B, Garin YJF, et al. Toxoplasmosis in Bone Marrow-Transplant Recipients: Report of Seven Cases and Review. Clin Infect Dis. 1992 Aug 1;15(2):267–70.

12. Matsuo Y, Takeishi S, Miyamoto T, Nonami A, Kikushige Y, Kunisaki Y, et al. Toxoplasmosis encephalitis following severe graft-vs.-host disease after allogeneic hematopoietic stem cell transplantation: 17 yr experience in Fukuoka BMT group: Toxoplasmosis encephalitis after allo-HSCT. Eur J Haematol. 2007 Oct;79(4):317–21.

13.   Martino R, Maertens J, Bretagne S, Rovira M, Deconinck E, Ullmann AJ, et al. Toxoplasmosis
after Hematopoietic Stem Cell Transplantation. Clin Infect Dis. 2000 Nov 15;31(5):1188–94.

14.   Menotti J, Garin YJF, Thulliez P, Sérugue MC, Stanislawiak J, Ribaud P, et al. Evaluation of a new
5'-nuclease real-time PCR assay targeting the Toxoplasma gondii AF146527 genomic repeat.
Clin Microbiol Infect. 2010 Apr;16(4):363–8.

15.   Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE Guidelines:
Minimum Information for Publication of Quantitative Real-Time PCR Experiments. Clin Chem.
2009 Apr 1;55(4):611–22.

16.   Foot AB, Garin YJ, Ribaud P, Devergie A, Derouin F, Gluckman E. Prophylaxis of toxoplasmosis
infection with pyrimethamine/sulfadoxine (Fansidar) in bone marrow transplant recipients.
Bone Marrow Transplant. 1994 Aug;14(2):241–5.

17.   Aerts R, Mercier T, Beckers M, Schoemans H, Lagrou K, Maertens J. Toxoplasmosis after
allogeneic haematopoietic cell transplantation: experience using a PCR-guided pre-emptive
approach. Clin Microbiol Infect. 2022 Mar;28(3):440–5.

18.   Conrad A, Le Maréchal M, Dupont D, Ducastelle-Leprêtre S, Balsat M, Labussière-Wallet H, et al.
A matched case–control study of toxoplasmosis after allogeneic haematopoietic stem cell
transplantation: still a devastating complication. Clin Microbiol Infect. 2016 Jul;22(7):636–41.

19.   Fricker-Hidalgo H, Bulabois C, Brenier-Pinchart M, Hamidfar R, Garban F, Brion J, et al. Diagnosis
of Toxoplasmosis after Allogeneic Stem Cell Transplantation: Results of DNA Detection and
Serological Techniques. Clin Infect Dis. 2009 Jan 15;48(2):e9–15.

20.   Paccoud O, Guitard J, Labopin M, Surgers L, Malard F, Battipaglia G, et al. Features of
Toxoplasma gondii reactivation after allogeneic hematopoietic stem-cell transplantation in a
high seroprevalence setting. Bone Marrow Transplant. 2020 Jan;55(1):93–9.

21.   Meers S, Lagrou K, Theunissen K, Dierickx D, Delforge M, Devos T, et al. Myeloablative
Conditioning Predisposes Patients for *Toxoplasma gondii* Reactivation after Allogeneic Stem
Cell Transplantation. Clin Infect Dis. 2010 Apr 15;50(8):1127–34.

22.   Guigue N, Léon L, Hamane S, Gits-Muselli M, Le Strat Y, Alanio A, et al. Corrigendum:
Continuous Decline of Toxoplasma gondii Seroprevalence in Hospital: A 1997–2014
Longitudinal Study in Paris, France. Front Microbiol. 2018 Nov 27;9:2814.

23.   Foroutan-Rad M, Majidiani H, Dalvand S, Daryani A, Kooti W, Saki J, et al. Toxoplasmosis in
Blood Donors: A Systematic Review and Meta-Analysis. Transfus Med Rev. 2016 Jul;30(3):116–
22.

24.   Reischl U, Bretagne S, Krüger D, Ernault P, Costa JM. Comparison of two DNA targets for the
diagnosis of Toxoplasmosis by real-time PCR using fluorescence resonance energy transfer
hybridization probes. BMC Infect Dis. 2003 Dec;3(1):7.

25.   Isa F, Saito K, Huang YT, Schuetz A, Babady NE, Salvatore S, et al. Implementation of Molecular
Surveillance After a Cluster of Fatal Toxoplasmosis at 2 Neighboring Transplant Centers. Clin
Infect Dis. 2016 Aug 15;63(4):565–8.

26.   Bretagne S, Costa JM, Kuentz M, Simon D, Vidaud M, Fortel I, et al. Late toxoplasmosis
evidenced by PCR in a marrow transplant recipient. Bone Marrow Transplant. 1995
May;15(5):809–11.

27.   Chandrasekar P, Momin F, The Bone Marrow Transplant Team. Disseminated toxoplasmosis in
marrow recipients: a report of three cases and a review of the literature. Bone Marrow
Transplant. 1997 Apr 1;19(7):685–9.

28.   Gajurel K, Dhakal R, Montoya JG. Toxoplasma prophylaxis in haematopoietic cell transplant
recipients: a review of the literature and recommendations. Curr Opin Infect Dis. 2015
Aug;28(4):283–92.

29.   Štajner T, Vujić D, Srbljanović J, Bauman N, Zečević Ž, Simić M, et al. Risk of reactivated
toxoplasmosis in haematopoietic stem cell transplant recipients: a prospective cohort study in a
setting withholding prophylaxis. Clin Microbiol Infect. 2022 May;28(5):733.e1-733.e5.

30.   Dupont D, Fricker-Hidalgo H, Brenier-Pinchart MP, Garnaud C, Wallon M, Pelloux H. Serology
for Toxoplasma in Immunocompromised Patients: Still Useful? Trends Parasitol. 2021
Mar;37(3):205–13.

1   **Table 1: Patient characteristics**

	Total		Total <D100		Without prophylaxis, < D100		With prophylaxis, <D100		Adjusted p-value (Bonferroni-Dunn)
	number	%	number	%	number	%	number	%	
Patients	52	100	44	84.6	30	57.7	14	26.9	
Male	31	59.6	26	59.1	16	53.3	10	71.4	0.33
Median age at alloHSCT (years) [IQR]	42 [28-52]		41 [28-52]		42 [25-52]		40 [30-52]		1
Median age at toxoplasmosis diagnosis (years) [IQR]	42 [28-52]		41 [28-52]		42 [25-52]		40 [30-52]		1
Underlying hematological malignancy									
Acute myeloid leukemia	21	40.4	16	36.4	10	33.3	6	42.9	0.49
Acute lymphoblastic leukemia	8	15.4	7	15.9	5	16.7	2	14.3	
Myelodysplastic syndrome	4	7.7	4	9.1	3	10	1	7.1	
Myeloproliferative neoplasm	9	17.3	9	20.5	8	26.7	1	7.1	
Non-Hodgkin lymphoma	2	3.8	1	2.3	0		1	7.1	
Hodgkin lymphoma	1	1.9	1	2.3	1	3.3	0		
Sickle cell disease	3	5.8	3	6.8	2	6.7	1	7.1	
Others (Aplastic anemia. Primary immune deficiency)	4	7.7	3	6.8	1	3.3	2	14.3	
Donor type									
Matched related	11	21.2	9	20.5	5	16.7	4	28.6	0.63
Matched unrelated	19	36.5	15	34.1	12	40	3	21.4	
Mismatched unrelated	18	34.6	17	38.6	11	36.7	6	42.9	
Haplo-identical	3	5.8	3	6.8	2	6.7	1	7.1	
Unknown	1	1.9	0		0		0		
Conditionning regimen									
Myelo-ablative	23	44.2	21	47.7	14	46,7	7	50	0.61
Reduced-intensity	26	50.0	21	47.7	14	46.7	7	50	
Sequential	3	5.8	2	4.5	2	6.7	0		
Including anti-thymoglobulin / alemtuzumab	39	75.0	34	77.3	26	86.7	8	57,1	
Stem cell source									
Peripheral blood	40	76.9	32	72.7	22	73.3	10	71.4	0.24
Bone marrow	7	13.5	7	15.9	6	20	1	7.1	
Cord blood	5	9.6	5	11.4	2	6.7	3	21.4	
Toxoplasma gondii donor IgG									
Positive	9	17.3	7	15.9	5	16.7	2	14.3	1
Negative	42	80.8	37	84.1	25	83.3	12	85.7	
Unknown	1	1.9	0		0		0		
Toxoplasma gondii recipient IgG									
Positive	47	90.4	41	93.2	30	100	11	78.6	0.027
Negative	5	9.6	3	6.8	0		3	21.4	

Donor / recipient *T. gondii* IgG									
D unknown / R negative	1	1.9	0		0		0		
D positive / R positive	7	13.5	6	13.6	5	16.7	1	7.1	0.06
D negative / R positive	40	76.9	35	79.5	25	83.3	10	71.4	
D positive / R negative	2	3.8	1	2.3	0		1	7.1	
D negative / R negative	2	3.8	2	4.5	0		2	14.3	
Time from alloHSCT to first positive *T. gondii* qPCR (mediane) [IQR]	26 [17-60]		23 [15.5-34]		19 [14-25]		48 [28-61]		0.0003
D0 to D30	30	57.7	30	68.2	25	83.3	5	35.7	
D31 to D100	14	26.9	14	31.8	5	16.7	9	64.3	0.004
D100 to D365	7	13.5	NA		NA		NA		
> D365	1	1.9	NA		NA		NA		NA
Median number of positive qPCR	2 [1-4]		3 [1-4]		3 [2-4]		1.5 [1-4]		1
Median time (days) from first positive to first negative *T. gondii* qPCR (n= 49)	11 [7-17]		11 [7-17]	n= 41	12 [7-15.5]	n= 28	11 [6-18]	n= 13	1
Relapse after alloHSCT	8	15.4	7	15.9	4	13.3	3	21.4	0.66
Median time from alloHSCT to relapse (days)	177 [99-381]		199 [127-392]		262 [140-472]		199 [149-307]		1
Toxoplasmosis after relapse	1		0		0		0		NA
Died after alloHSCT	22	42.3	19	43.2	10	33.3	9	64.3	0.1
Median time from alloHSCT to death (days)	155 [77-253]		139 [65.5-220.5]		66 [50-173]		182 [139-234]		1
Cause of death									
Graft-versus-host disease	10	45.5	10	52.6	5	50.0	5	55.6	
Graft-versus-host disease and toxoplasmosis	2	9.1			2	20.0	0		
Relapse	3	13.6	3	15.8	1	10.0	2	22.2	0.45
Relapse and toxoplasmosis	1	4.5	0		0		0		
Infection (other than toxoplasmosis)	6	27.3	6	31.6	4	40.0	2	22.2	
Chemotherapy at toxoplasmosis	1		0		0		0		NA
Immunosuppressive treatment at toxoplasmosis	50		42	95.5	28	93.3	14	100	1
Steroids	23	46	16	36.4	10	33.3	6	42.9	0.73
Calcineurin inhibitor	37	74	33	75.0	22	73.3	10	71.4	1
Mycophenolate mofetil	13	26	13	29.5	13	43.3	0		0.0034
Ruxolitinib	2	4	2	4.5	0		2	14.3	0.09
Anti-TNF	2	4	1	2.3	0		1	7.1	0.31
Everolimus	3	6	2	4.5	0		2	14.3	0.09
≥ 2 immunosuppressants	28	56	23	52.3	17	56.7	5	35.7	0.33
Steroids + ≥ 1 immunosuppressant	17	34	12	27.3	7	28.3	5	35.7	0.47
Median gamma globulin level at toxoplasmosis (g/L)	5.05 [3.1-7.1]		5.9 [3.7-7.7]		6 [4.7-6.9]		3.5 [2.5-8.6]		1

Median white blood cells at toxoplasmosis (G/L)	2.9 [0.9-5.9]		2.2 [0.4-5.3]		1.2 [0.1-3.7]		4.9 [2.3-7.2]		1
Median peripheral blood lymphocytes at toxoplasmosis (G/L)	0.2 [0-0.5]		0.13 [0-0.42]		0.1 [0-0.25]		0.4 [0.1-1.1]		0.024
Peripheral blood positive toxoplasmosis qPCR	52		44		30		14		NA
T. gondii infection	45	86.5	40	90.9	28	93.3	12	85.7	
T. gondii disease	7	13.5	4	9.1	2	6.7	2	14.3	
Central nervous system	7	13.5	4	9.1	2	6.7	2	14.3	
Neurological symptoms	3								0.51
Symptoms at first positive *T. gondii* qPCR	11	20.8	7	15.9	6	20.0	1	7.1	
Fever	9								
Radiologic work-up not performed (no symptoms)	20	38.5	18	40.9	10	33.3	8	57.1	
Radiologic work-up performed	33	63.5	26	59.1	20	66.7	6	42.9	
CNS MRI	22	42.3	18	40.9	13	43.3	5	35.7	
including abnormal CNS MRI findings	7		4	9.1	2	6.7	2	14.3	
CNS TDM	7	13.5	6	13.6	5	16.7	1	7.1	
including abnormal CNS TDM findings	0		0		0		0		
Thoraco-abdominal TDM	22	42.3	20	45.5	15	50.0	5	35.7	
including toxoplasmosis-related abnormal findings	0		0		0		0		
Ophthalmological examination	10	19.2	8	18.2	6	20.0	2	14.3	
including toxoplasmosis-related abnormal findings	0		0		0		0		

Figure legends

Figure 1a: Screening work-up

Figure 1b: Therapeutic options in case of positive qPCR

Prophylactic treatment included: prophylactic CTX (400 mg/day or 800 mg/day given three

days/week). pyrimethamine/sulfadoxine (1 500 mg/75 mg once weekly) or atovaquone (750mg bid).

Non-prophylactic treatment included curative treatment (high-dose CTX (2 400-4 800 mg/day) or

pyrimethamine/sulfadiazine) and intermediate-dose CTX (800-1 600mg/day).

Figure 2a: Toxoplasmosis diagnosed before D100 in patients without *Toxoplasma*

prophylaxisFigure 2b: Toxoplasmosis diagnosed before D100 in patients receiving anti-

***Toxoplasma* prophylaxis**

Figure 3: Evolution of parasitic load by qPCR before and treatment implementation

Five illustrative cases showing the kinetics of *Toxoplasma gondii* qPCR results on blood sample. From

a starting sample with 45 Cq value corresponding to no detectable circulating DNA, the five patients

had a decrease of Cq values (i.e. an increase of blood parasite load) until the day of treatment (D0)

followed by an increase of Cq values (i.e. the decrease of blood parasite load) until negation for four

patients and a persistent parasite load in one patient.

Figure 4: Toxoplasmosis diagnosed after D100

Figures

Figure 1

Abbreviations: alloHSCT: allogeneic hematopoietic stem cell transplantation; CTX: cotrimoxazole

1   **Figure 2**

3   Abbreviations: d: day; P: pyrimethamine; So: sulfadoxine; Sa: sulfadiazine; CTX: cotrimoxazole; CR:

4   complete remission: CNS: central nervous system. IV: intra-venous. Treatment length before PCR

5   negativity is indicated in brackets.

1   **Figure 3**

1   **Figure 4**

3